RIGEL PHARMACEUTICALS, INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $217.89 million for the 9-month period ending 2014-09-30, per its 10-Q filed 2014-11-04.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2014-11-04
- RIGEL PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2014-09-30 was $53.87M, a 34.25% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2014-06-30 was $73.75M, a 26.60% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2014-03-31 was $90.28M, a 29.14% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2013-12-31 was $56.17M, a 33.84% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2013 was $365.97M, a 16.77% decline from fiscal 2012.
- RIGEL PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2012 was $439.72M, a 5.83% increase from fiscal 2011.
- RIGEL PHARMACEUTICALS, INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2011 was $415.49M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2014-09-30 | $53.87M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $127.62M derived: sum of 2 quarters · filed 2014-11-04 | $217.89M 10-Q · filed 2014-11-04 | $274.06M derived: sum of 4 quarters · filed 2014-11-04 |
| 2014-06-30 | $73.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $164.03M 10-Q · filed 2014-08-05 | $220.19M derived: sum of 3 quarters · filed 2014-08-05 | $302.12M derived: sum of 4 quarters · filed 2014-11-04 |
| 2014-03-31 | $90.28M 10-Q · filed 2014-05-07 | $146.44M derived: sum of 2 quarters · filed 2014-05-07 | $228.37M derived: sum of 3 quarters · filed 2014-11-04 | $328.85M derived: sum of 4 quarters · filed 2014-11-04 |
| 2013-12-31 | $56.17M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-04 | $138.09M derived: sum of 2 quarters · filed 2014-11-04 | $238.57M derived: sum of 3 quarters · filed 2014-11-04 | $365.97M 10-K · filed 2014-03-04 |
| 2013-09-30 | $81.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $182.41M derived: sum of 2 quarters · filed 2014-11-04 | $309.80M 10-Q · filed 2014-11-04 | $394.70M derived: sum of 4 quarters · filed 2014-11-04 |
| 2013-06-30 | $100.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | $227.88M 10-Q · filed 2014-08-05 | $312.77M derived: sum of 3 quarters · filed 2014-08-05 | $390.51M derived: sum of 4 quarters · filed 2014-08-05 |
| 2013-03-31 | $127.40M 10-Q · filed 2014-05-07 | $212.29M derived: sum of 2 quarters · filed 2014-05-07 | $290.03M derived: sum of 3 quarters · filed 2014-05-07 | |
| 2012-12-31 | $84.90M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-04 | $162.63M derived: sum of 2 quarters · filed 2014-03-04 | $439.72M 10-K · filed 2014-03-04 | |
| 2012-09-30 | $77.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-05 | $354.83M 10-Q · filed 2013-11-05 | ||
| 2012-06-30 | $277.09M 10-Q · filed 2013-08-06 | |||
| 2011-12-31 | $415.49M 10-K · filed 2014-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |